ABSTRACT
Using proteome databases and exploiting the concept that a rare sequence is a potential epitope, epitopic sequences derived from Porphyromonas gingivalis fimA type I protein were examined for pentapeptide sequence similarity score to the human proteome. We obtained data showing that most of the linear bacterial determinants are (or are formed by) peptide fragment(s) absent (or rarely found) in the human proteins. These results seem to confirm the hypothesis that low-sequence similarity may contribute to shape the epitope repertoire and provides a potential tool for designing new immunotherapeutic approaches to apply in Porphyromonas gingivalis infected periodontitis.
INTRODUCTION
Porphyromonas gingivalis, a black pigmented gram-negative anaerobic bacterium, is an important etiologic agent of chronic inflammatory disease of periodontium (1, 2). In particular, it has been associated with aggressive forms of periodontitis and its presence in patients' saliva is nowadays considered of high sensitivity in diagnosing parodontitis (3). In recent years, P. gingivalis-mediated periodontal disease has been linked to several systemic conditions such as atherosclerotic cardiovascular disease (4, 5), pregnancy complications (6), diabetes (7, 8) , pulmonary disease (9, 10), osteoporosis (11) and cancer (12, 13).
P. gingivalis expresses fimbriae on the cell surface, which are recognized as major virulence factors influencing disease initiation and progression (14-18) and, consequently, are considered as promising candidate antigens for vaccine development (18). This consideration is supported by the following observations. First, anti-P. gingivalis fimbriae antibodies occur in the serum of patients with adult periodontitis (19, 20) , and antibodysecreting cells specific for P. gingivalis fimbriae have been found in the inflamed gingival tissue of periodontitis patients (21, 22); second, monoclonal antibodies against a particular subunit of P. gingivalis fimbriae, the so-called major fimbrial subunit protein type-1 (fimA, type I) blocked bacterial adhesion to human buccal epithelial cells (23-25). As a further note, immunization in a rat animal model with purified P. gingivalis fimbriae or a fimbriae-derived synthetic peptide (aa sequence: GKTLAEVKALTTELTAENQE and VAPAADAPQGFTVLENDYSA, respectively), has been reported to induce protective immunity against periodontal destruction (26).
Fimbriae of P. gingivalis are classified into six genotypes (types I to V and Ib), based on the genotype of the fimA genes encoding the fimbrial subunits (27). FimA type I P. gingivalis strains, as well as synthetic fimA type I peptide segments, exhibit chemotactic activity, induce production of pro-inflammatory cytokines such as tumour necrosis factor-a, and interleukins 1, 6, and 8 in human monocyte and macrophage cultures, and haemagglutinating activity (28).
Given these premises, P. gingivalis fimbriae appear to be highly immunogenic and, consequently, might be an ideal target for vaccine. Recent studies have provided convincing evidence that antibodies can protect against P. gingivalis infections (16-18, 29). Passive immunization using mono-and polyclonal antibodies, and humoral immune responses against specific P. gingivalis antigens in experimental animals have shown that antibodies may play an anti-P. gingivalis role. However, in face of such encouraging data, the epitopic characterization of P. gingivalis antigens is performed antigen-by-antigen, searching for specific epitope features for each P. gingivalis protein antigen (1, 2, 14-18, 29, 30). More in general, the molecular basis that determine the immunogenicity of specific peptide sequences remain unclear (31, 32). Little is known about the structurefunction relationship(s) of protein sequences in immunology. Such a context makes difficult the development of preventive/therapeutic vaccines against infectious agents. Within this framework, we follow the rationale that rare peptide sequences (that is, peptide motifs rarely found in the host proteins), have the potential to elicit immune response(s). Unique protein sequences are more likely to evoke an immune response than highly repeated motifs, which are expected to be immunologically silenced by the host's tolerance mechanisms. The relationship between sequence rarity and peptide immunoreactivity has been already validated in cancer, autoimmunity, and infectious disease models; specific targeting of peptide regions with no or limited sequence similarity to the host proteome was demonstrated using mono-and/or polyclonal antibodies against EC Her-2/Neu oncoprotein (33), desmoglein-3 (34), melan-a/MART-1 (35), high-molecular-weight melanoma associated-antigen (36, 37) , tyrosinase (38, 39) , prostate specific-antigen (40), HPV16 E7 (41), HCV (42) , and influenza A (43) proteins. In addition, the data received substantial support from epitope mapping literature revealing that most peptide epitopes obey the low-similarity rule (44) (45) (46) (47) (48) .
In the present study, we analyze P. gingivalis fimA type I protein searching for potential immunogenic peptides that might be used in anti-P. gingivalis immunotherapies. We compare validated P. gingivalis fimA type I epitopes currently cataloged at the Immune Epitope Database and Analysis Resources (IEDB) (http://www.immuneepitope.org/) (49) , and report that most of P. gingivalis epitopes involved in the immune response, and already experimentally validated by Ogawa (28), are characterized by a low level of similarity to the host proteome.
METHODS
The primary amino acid (aa) sequence of P. gingivalis fimA type I protein, corresponding to GenBank accession number: M19405.1; NCBI Taxonomic identifier: 837; UniProtKB/Swiss-Prot accession number: P0C940; length: 347aa (50); was used in the similarity analysis to the human proteome.
The bacterial sequence under analysis was dissected into 343 sequential pentapeptides, overlapping by 4 residues, that is MVLKT, VLKTS, LKTSN, KTSNS etc.
Each bacterial pentapeptide was used as a probe to scan the entire set of proteins forming the human proteome for identical matches (51) . The pentapeptide matching analysis utilized PIR protein database and perfect peptide match program (http://pir.georgetown.edu/pirwww/) (52) . The number of matches of each bacterial pentamer to the human proteome varied in a wide range, from no matches to hundreds of matches. A pentapeptide that has five (or less than five) perfect matches to the host proteome was considered to be a low-similarity sequence, that is, a rare fragment (33-44, 53). Pentapeptides were used because the literature indicates that five to six amino acids are a sufficient minimal determinant for an epitope-paratope interaction, and thus a pentapeptide can act as an immune unit and play a crucial role in cell immunoreactivity and antigen-antibody recognition (54, 55) . Pentapeptide similarity is defined as number of occurrences (matches) in the human proteins. On the whole, exact peptide-peptide profiling of the fimbrial antigen versus the human proteome shows that the P. gingivalis fimA type I protein pentapeptide overlap to the human proteins amounts to 329 bacterial pentapeptides repeatedly occurring throughout the human proteome for a total of 2,292 occurrences (Figure 1) . Hence, it is logical to conclude that a vaccine based on the bacterial pentapeptides not present in the human proteome might have the potential of hitting exclusively the bacterial antigen without cross-reacting with the human host.
Peptide sequences unique to Porphyromonas gingivalis fimA type I protein: immunogenicity analysis
To test the feasibility of utilizing peptide fragments unique to the fimbrial antigen in anti-P. gingivalis vaccine design, we analyzed the similarity level of experimentally validated P. gingivalis fimA type I epitopes currently cataloged at the IEDB. At the time of the analysis, the IEDB contained 23 P. gingivalis fimA epitopes that had tested as positive in immunoassays (28). Table 1 clearly shows that all P. gingivalis fimA type I immunoreactive epitopes are characterized by the presence of pentapeptides rarely (or never) found in human proteins.
DISCUSSION
Utilization of short peptide modules rather than full-length P. gingivalis antigens in vaccines may increase specificity and efficacy. It has been understood since the 1980s that chemically synthesized small peptides can induce antibodies that react with intact proteins (56) . Furthermore, peptide-based vaccines have been successfully used against several pathologies and infectious diseases. For example, tumour antigen-derived peptides evoked potent antitumour immunity in the murine melanoma M-3 (57); cytotoxic CD4+ and CD8+ T lymphocytes generated by mutant p21-ras (12Val) peptide vaccination selectively killed autologous tumour cells carrying this mutation (58); Her-2/neu peptide (aa 657-665) is an immunogenic epitope of Her-2/neu oncoprotein with potent antitumour properties (59); synthetic peptides identified as antigenic sites on the S1 subunit of pertussis toxin induced especially high antibody titres against native pertussis toxin in mice (60); a linear peptide containing minimal T-and B-cell epitopes of Plasmodium falciparum circumsporozoite protein provided protection against a transgenic sporozoite challenge (61); the 15-mer aminoacid sequence 101-115 (PPAYEKLSAEQSPPP) of the Melan-A/MART-1 melanoma antigen has been shown to be a good target for a vigorous and safe immunotherapy (62) .
Based on these scientific premises, this study explored the primary sequence of P. gingivalis fimA type I protein to define and characterize P. gingivalis epitopes that could be used for effective and safe anti-P. gingivalis immunotherapy. We observed that the immunological potential carried by the P. gingivalis antigens is localized in rare peptide fragments, thus confirming the relationship between low-similarity and immunogenicity (33-44). Sequences containing pentapeptide fragment(s) with low similarity to the host proteome appear to be those involved in the humoral antibody recognition of the P. gingivalis antigen, thus indicating that P. gingivalis antigenic motifs rarely found in host proteins are more likely to evoke an immune response. In short, these findings provide a method for investigating the immune potential of the P. gingivalis proteome, and, thus, may help fight P. gingivalis infection, one of the primary challenges in current periodontitis research. This study might also contribute to accelerate the epitopic characterization of P. gingivalis antigens which advances slowly, antigen-by-antigen (1, 2, 14-18, 28, 29).
Moreover, using exact immunogenic P. gingivalis peptide sequences may provide not only effective active or passive immunotherapeutic anti-P. gingivalis approaches but, in addition, might abolish the risk of adverse effects, which remains a major obstacle to antibody-based therapies (63) (64) (65) (66) (67) . Adverse events are possibly caused by crossreactivity that may result from using entire microbial antigens, because of the presence of peptide sequences common to microbes and humans (68, 69) (see also Figure  1 ). Using low-similarity peptides may help develop effective vaccines exempt of adverse side-effects (70), since the target sequence sites are present in the microbial organism only.
In conclusion, the findings of the present study may provide guidance in the analysis, identification, and utilization of the B-cell response in vaccination against P. gingivalis-associated periodontitis. 
